Q2 2025 Financial Performance - Net income reached $6.9 million, a year-over-year increase of $38 million[13] - Earnings per share (EPS) amounted to $0.14, up $0.92 year-over-year[13] - Return on equity (ROE) achieved 7.4%, a 41 percentage point increase year-over-year[13] - Adjusted EPS was $0.31, compared to $0.08 in Q2 2024[14] - Adjusted ROE was 16%, versus 3.5% in Q2 2024[14] - Adjusted EBITDA totaled $31 million, a year-over-year increase of $1 million[14] Credit Quality and Operating Efficiency - The net charge-off (NCO) rate was 11.9%, a decrease of 41 basis points year-over-year, with dollar net charge-offs down by 6% year-over-year[14] - The 30+ day delinquency rate was 4.4%, a decrease of 54 basis points year-over-year[14] - Operating expenses (OpEx) amounted to $94.4 million, a 13% year-over-year decline[14] - Q2 risk adjusted net interest margin ratio improved by 192 bps Y/Y to 16.3%[16] - Q2 Adjusted OpEx ratio improved by 46 bps Y/Y to 13.3%[16] Strategic Focus and Future Outlook - The company is raising its 2025 adjusted EPS expectations by 8% at the midpoint[11] - Full-year 2025 adjusted EPS guidance of $1.20-$1.40 reflects 67%-94% growth[14] - The company anticipates full-year 2025 operating expenses of $380 million, a $10 million reduction from prior expectations and a $30 million reduction from 2024's $410 million[14] - The company expects approximately 10% full-year 2025 loan origination growth[14] - Secured personal loan portfolio grew 58% year-over-year in Q2, reaching 7% of owned portfolio[16]

Financial Performance - ACIC's Non-GAAP Core Income for Q2 2025 increased by $7.2 million (+36.4%) year-over-year to $26.8 million ($0.54 per share) from $19.6 million ($0.40 per share) [9] - Net premiums earned grew by $15.0 million (+23.8%) year-over-year to $78.4 million [9] - The combined ratio decreased to 60.6% from 64.9% in the prior year, and the Non-GAAP underlying combined ratio decreased to 62.2% from 66.4% [9] - Stockholders' equity increased by $56.6 million from December 31, 2024, to $292.3 million, or $6.00 per share [9] - Net income from continuing operations increased by $8.9 million (+46.6%) year-over-year to $28.0 million [14] Balance Sheet & Investment - Total Assets reached $1.35 billion as of June 30, 2025 [6] - Total Equity was $292.3 million as of June 30, 2025 [6] - Cash & investments increased by 34.3% from December 31, 2024, to $726.243 million [15] - Total Cash & Investments increased by 27.7% from Mar. 31, 2025 to $726.243 million [17] Other Highlights - The company completed its Core CAT reinsurance program effective June 1, 2025, with a risk-adjusted decrease of -12.4% [9] - ACIC was upgraded to investment grade status (BBB-) by KBRA on 7.21.25, saving approximately $1.5 million per year in interest expense [9]

competitors in the education services industry, and therefore, our measures may not be comparable to those of other companies. 2 Highlights Cycle 2025 2Q25 Earnings Presentation August 6, 2025 INDEX DISCLAIMER This presentation contains forward-looking statements that can be identified using forward-looking words such as "anticipate," "believe," "could," "expect," "should," "plan," "intend," "estimate" and "potential," among others. Forward-looking statements appear in several places in this presentation an ...

Financial Performance - Q2 2025 - Total revenue reached $811 million in Q2 2025, a 16% year-over-year increase[5] - Adjusted EBITDA for Q2 2025 was $138 million, up 26% year-over-year[5] - Core revenue also grew by 16% in Q2 2025[7] - Screening revenue increased by 18% from $532 million in Q2 2024 to $628 million in Q2 2025[8] - Precision Oncology core revenue increased by 9% from $165 million in Q2 2024 to $179 million in Q2 2025[8] Profitability and Cash Flow - Adjusted EBITDA margin improved to 17% in Q2 2025, an increase of 130 basis points[11] - Free cash flow was $46 million[11] Updated 2025 Guidance - Total revenue guidance updated to $3.13 billion - $3.17 billion, an increase of $55 million at the midpoint[13] - Screening revenue guidance updated to $2.44 billion - $2.47 billion, an increase of $48 million at the midpoint[13] - Adjusted EBITDA guidance updated to $455 million - $475 million, an increase of $25 million at the midpoint[13] Cost Savings Initiatives - A multi-year productivity program aims for $150 million in annual run-rate cost savings by 2026[16, 17]

Earnings Supplement While we anticipate volumes to remain relatively stable through the second half of 2025, we believe we are well positioned for renewed growth in 2026 with improved underwriting and pricing actions. Our CU/Bank channel loans typically have higher program fees compared to our OEM loans, which leads to more favorable economics. Q2 2025 Q2 2025 Financial Highlights Q2 2025 Q2 2024 Revenue $25.3 million $26.7 million Adj. EBITDA1 $4.1 million $6.8 million Total Certs 26,522 28,963 (1) See rec ...

Company Overview - The Honest Company was launched in 2012 with a focus on clean ingredients and sustainability[15] - The company's mission is to challenge ingredients, ideals, and industries to protect loved ones[16] - The Honest Standard includes banning over 3,500 ingredients and utilizing in-house labs for innovative formulas[18, 19] - The company is the 1 natural brand in baby personal care[20] and baby wipes[22] Financial Performance - In 2024, revenue reached $378 million, a 10% increase year-over-year[38] - Gross margin in 2024 was 38%, representing a 900 bps improvement year-over-year[38] - Adjusted EBITDA for 2024 was $26 million, a $37 million increase year-over-year[38] - The company had $75 million in cash and $0 debt at the end of 2024[29] - Q1 2025 revenue was $97 million, a 13% increase year-over-year[41] - Q2 2025 revenue was $93 million, a 0.4% increase year-over-year[44] Growth Strategy - The company is focused on brand maximization, margin enhancement, and operating discipline[28] - Household penetration has increased by 20% since 2021[24] - The company aims to expand distribution by increasing total distribution points[59] - There is a large runway for growth into more doors, with approximately 45,000 doors selling Honest products compared to a leading competitor's ~90,000 doors[66]

| . | | --- | | . | | = . | | . | | . 1 ロ | | ロ . - | | . | Q2 2025 Earnings Presentation August 6, 2025 Safe Harbor Statement Information, statements and projections contained in these presentation slides and related conference call concerning Fortinet's business outlook, the third quarter and full year 2025 guidance, and future prospects and expectations are forward-looking statements that involve risks and uncertainties. These forward-looking statements include statements regarding any indications relate ...

Financial Performance - Q2 2025 - Total company net sales reached $31.1 million, a 37% year-over-year increase[10] - Tru Niagen® net sales were $22.7 million, representing a 22% year-over-year increase[10] - Niagen® ingredient sales surged to $7.4 million, marking a 135% year-over-year increase[10] - Gross margin improved to 65.0%, up 480 basis points year-over-year[10] - Net income was $3.6 million, or $0.05 earnings per share, a $3.6 million year-over-year increase[10] - Adjusted EBITDA reached $5.0 million, a $3.5 million year-over-year increase[10] Financial Position - Cash provided from operations year-to-date was $9.1 million, with a cash balance of $60.5 million and no debt[10] Sales Mix - Q2 2025 - E-commerce accounted for 57% of net sales, while Watson's & Other B2B represented 25%[26] - Food-grade Niagen® contributed 14% to net sales, and Analytical Reference Standards & Services accounted for 3%[26] - Other Ingredients made up 1% of net sales[26] 2025 Outlook - The company anticipates net sales growth between 22% and 27% year-over-year[10] - Sales and marketing expenses are expected to increase in absolute dollars but decrease as a percentage of net sales year-over-year[10]

Company Overview AUGUST 6, 2025 Ben diagnosed 2024 Izzy diagnosed 2014 Safe Harbor Certain statements in this presentation constitute forward-looking statements, including, without limitation, statements about: the perceived advantages of our products relative to competitive products and technologies; our anticipated growth and other measures of future operating results and financial performance; the development and commercialization of new products; our ability to secure and maintain necessary regulatory a ...

Investor Presentation Q2 2025 Safe Harbor Statement 2 Our Mission Help millions of organizations grow better Our Aspiration Be the #1 AI-powered customer platform for scaling companies 3 Fueling Growth for Scaling Businesses with HubSpot's AI-Powered Customer Platform Marketplace Academy Network Engagement Hubs Unified data Embedded AI Ecosystem Copilot Agents AI Features Smart CRM 4 This presentation includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Refor ...